Valuation: Evotec

Market Cap 609M 693M 567M 521M 977M 66.25B 994M 6.72B 2.63B 32.86B 2.6B 2.55B 114B P/E 2026 *
-3.97x
P/E 2027 * -9.92x
Enterprise Value 650M 741M 605M 557M 1.04B 70.77B 1.06B 7.18B 2.81B 35.1B 2.78B 2.72B 121B EV / Sales 2026 *
1.08x
EV / Sales 2027 * 0.97x
Free-Float
89.91%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 55 30/06/2024
Director of Finance/CFO - 30/04/2026
Chief Operating Officer - 30/04/2026
Director TitleAgeSince
Director/Board Member 58 18/06/2019
Director/Board Member 64 31/05/2021
Director/Board Member 43 21/06/2022
Change 5-day change 1-year change 3-year change Capi.($)
-72.92%0.00% - - 692M
+0.14%-0.67%-0.88%+11.02% 47.74B
-2.45%-0.39%+390.02%+610.15% 39.98B
+0.56%+2.56%+10.97%+45.17% 36.23B
+13.60%+19.22%+21.55%+6.29% 35.59B
-0.73%+2.78%+4.65%+41.16% 27.91B
-1.90%-2.83% - - 16.71B
-0.61%+9.45%+28.45%+128.38% 16.45B
+2.39%-1.64%+4.74%+9.95% 13.21B
+7.43%+8.87%-4.36%-28.06% 12.93B
Average -5.41%+2.78%+56.89%+103.01% 27.42B
Weighted average by Cap. +1.80%+2.95%+75.29%+129.59%

Financials

2026 *2027 *
Net sales 600M 683M 558M 514M 963M 65.28B 979M 6.62B 2.59B 32.37B 2.57B 2.51B 112B 736M 839M 685M 630M 1.18B 80.13B 1.2B 8.13B 3.18B 39.74B 3.15B 3.08B 137B
Net income -147M -168M -137M -126M -236M -16.02B -240M -1.63B -636M -7.95B -630M -616M -27.45B -47.45M -54.07M -44.19M -40.64M -76.19M -5.17B -77.5M -524M -205M -2.56B -203M -199M -8.85B
Net Debt 41.5M 47.29M 38.65M 35.54M 66.63M 4.52B 67.77M 458M 179M 2.24B 178M 174M 7.74B 105M 120M 97.93M 90.07M 169M 11.45B 172M 1.16B 455M 5.68B 450M 440M 19.62B
Logo Evotec
Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
AAA
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
8
Last Close Price
3.424EUR
Average target price
4.900EUR
Spread / Average Target
+43.11%

Quarterly revenue - Rate of surprise